Your browser doesn't support javascript.
loading
A path to translation: How 3D patient tumor avatars enable next generation precision oncology.
Bose, Shree; Barroso, Margarida; Chheda, Milan G; Clevers, Hans; Elez, Elena; Kaochar, Salma; Kopetz, Scott E; Li, Xiao-Nan; Meric-Bernstam, Funda; Meyer, Clifford A; Mou, Haiwei; Naegle, Kristen M; Pera, Martin F; Perova, Zinaida; Politi, Katerina A; Raphael, Benjamin J; Robson, Paul; Sears, Rosalie C; Tabernero, Josep; Tuveson, David A; Welm, Alana L; Welm, Bryan E; Willey, Christopher D; Salnikow, Konstantin; Chuang, Jeffrey H; Shen, Xiling.
Afiliação
  • Bose S; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27708, USA.
  • Barroso M; Department of Molecular and Cellular Physiology, Albany Medical College, Albany, NY 12208, USA.
  • Chheda MG; Department of Medicine, Washington University in St. Louis, St. Louis, MO, 63110 USA.
  • Clevers H; Oncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Center, Uppsalalaan 8, Utrecht, 3584 CT, Netherlands; Research and Early Development (pRED) of F. Hoffmann-La Roche Ltd, Roche Pharma, Basel, Switzerland.
  • Elez E; Vall d'Hebron Hospital Campus and Institute of Oncology, International Oncology Bureau-Quiron, University of Vic-Central University of Catalonia, Barcelona, 08035 Spain.
  • Kaochar S; Department of Medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Kopetz SE; The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Li XN; Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Meyer CA; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA; Department of Pharmacology an
  • Mou H; The Wistar Institute, Philadelphia, PA 19104, USA.
  • Naegle KM; Department of Biomedical Engineering and the Center for Public Health Genomics, University of Virginia, Charlottesville, VA 22903, USA.
  • Pera MF; The Jackson Laboratory, Bar Harbor, ME 04660, USA.
  • Perova Z; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Politi KA; Departments of Pathology and Internal Medicine (Medical Oncology), Yale School of Medicine and Yale Cancer Center, New Haven, CT 06510, USA.
  • Raphael BJ; Department of Computer Science, Princeton University, Princeton, NJ 08540, USA.
  • Robson P; The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA; Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, Farmington, CT 06032, USA; Institute for Systems Genomics, University of Connecticut, Farmington, CT 06032, USA.
  • Sears RC; Department of Medical and Molecular Genetics, Oregon Health & Science University, Portland, OR 97201, USA.
  • Tabernero J; Vall d'Hebron Hospital Campus and Institute of Oncology, International Oncology Bureau-Quiron, University of Vic-Central University of Catalonia, Barcelona, 08035 Spain.
  • Tuveson DA; Lustgarten Foundation Pancreatic Cancer Research Laboratory at Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
  • Welm AL; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
  • Welm BE; Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
  • Willey CD; Department of Radiation Oncology, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Salnikow K; Division of Cancer Biology, National Cancer Institute, NIH, Rockville, MD 20850, USA. Electronic address: salnikok@mail.nih.gov.
  • Chuang JH; The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA; Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, Farmington, CT 06032, USA; Institute for Systems Genomics, University of Connecticut, Farmington, CT 06032, USA. Electronic address: jeff.
  • Shen X; Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA. Electronic address: xiling.shen@terasaki.org.
Cancer Cell ; 40(12): 1448-1453, 2022 12 12.
Article em En | MEDLINE | ID: mdl-36270276
ABSTRACT
3D patient tumor avatars (3D-PTAs) hold promise for next-generation precision medicine. Here, we describe the benefits and challenges of 3D-PTA technologies and necessary future steps to realize their potential for clinical decision making. 3D-PTAs require standardization criteria and prospective trials to establish clinical benefits. Innovative trial designs that combine omics and 3D-PTA readouts may lead to more accurate clinical predictors, and an integrated platform that combines diagnostic and therapeutic development will accelerate new treatments for patients with refractory disease.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos